Evidence synthesis for the modern tumor board.
Galen helps oncology teams prepare more thorough cases in less time — surfacing relevant evidence from across the biomedical literature, organized by strength and relevance.
Deeper preparation, less time.
Synthesizes evidence from peer-reviewed databases so you’re not reading abstracts at midnight.
Organized by evidence strength.
Every finding tagged by source tier: clinical trials, experimental research, computational inference.
Fits your workflow.
Designed for the way tumor boards already work — case-by-case, focused, time-boxed.
See what evidence synthesis looks like.
A de-identified case showing how Galen prepares evidence for review.
Example case — de-identified
Stage IIIB NSCLC — multi-mutation profile
Genomic profile
Causal traces surfaced
BRAF V600E constitutively activates MAPK pathway → Dabrafenib + trametinib targets this cascade
Clinical · COMBI-d Trial, NEJM 2014
TP53 R175H loss of tumor suppression + gain-of-function activity → Associated with resistance to single-agent BRAF inhibition
Research · Walerych et al., Nature Cell Biology 2012
CDKN2A deletion loss of p16/CDK4 cell-cycle checkpoint → CDK4/6 inhibitor (palbociclib) under investigation
Research · NCT03454919, Phase II
Resistance mechanisms flagged
MAPK pathway reactivation via MEK2 C125S — documented in BRAF V600E patients on combination therapy.
Research · Long et al., Cancer Discovery 2014
TP53 gain-of-function may stabilize BRAF-mutant signaling under therapeutic pressure.
Computational · Galen causal model
Get in touch
Tell us about your practice and we’ll follow up within one business day.